Efficacy and safety of basiliximab in pediatric liver transplantation
10.3760/cma.j.issn.0254-1785.2017.10.004
- VernacularTitle:巴利昔单抗在儿童肝移植中应用的有效性及安全性评价
- Author:
Haixia REN
1
;
Wei GAO
;
Fan CHEN
;
Kai WANG
;
Chao SUN
;
Haohao LI
;
Shanni LI
Author Information
1. 300192,天津市第一中心医院药学部
- Keywords:
basiliximab;
liver tranplantation;
children;
safety;
kidneyfunction;
electrolyte
- From:
Chinese Journal of Organ Transplantation
2017;38(10):594-597
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety of basillixirnab in pediatric liver transplantation (PLT).Methods Retrospectively,256 cases (hospitalized from Jan.2014 to Dec.2015) were divide into groups in terms of inclusion and exclusion criteria.A group of 137 children transplanted under tacrolimus-steroid as baseline immunosuppressants combined with basilliximab induction (basilliximab group),and a group of 84 PLT recipients were treated with a tacrolimus-steroid regimen (control group) were set up.Two groups were compared regarding rejection incidence,infectious complications,as well as the kidney function and electrolyte within the three months after operations.Results Infectious complications and rejection incidence were 32.8％ and 8.3％ in basilliximab group,versus 27.4％ and 14.3％ in control group (all P＞0.05).There was no statistically significant difference in the levels of blood urea nitrogen,creatinine,calcium,potassium and phosphate between two groups.Conclusion Although basilliximab may decrease the rejection incidence,the effect is not significant.The main reason may be the small sample size,and further observation is still needed.
